Androgen ablation for low-risk prostate cancer is common among male hip fracture patients

References

• Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, Damber J-E, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 2009;373:301–8.
   PubMed Web of Science ®Google Scholar
• Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–81.
   PubMed Web of Science ®Google Scholar
• Shanihian VB. Kuo Y-f, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;103:1615–24.
   Google Scholar
• Greenspan SL, Coates P, Sereika S, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410–17.
   PubMed Web of Science ®Google Scholar
• Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006;175:1679–83.
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo Y-f, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–64.
   PubMed Web of Science ®Google Scholar
• Schulman CC, Irani J, Morote J, Schalken JA, Montorsi F, Closta PL, et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol Suppl 2010;9:675–91.
   Web of Science ®Google Scholar
• Alibhai SMH, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, et al. Impact of androgen deprivation therapy on physical function and quality of life in men with non-metastatic prostate cancer. J Clin Oncol 2010;28:5038–45.
   PubMed Web of Science ®Google Scholar
• Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136–9.
   PubMed Web of Science ®Google Scholar
• Panula J, Pihlajamäki H, Sävelä M, Jaatinen PT, Vahlberg T, Aarnio P, et al. Cervical hip fracture in a Finnish population: incidence and mortality. Scand J Surg 2009;98:180–8.
   PubMed Web of Science ®Google Scholar
• Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005–7.
   PubMed Web of Science ®Google Scholar
• Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA. Pamindronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–55.
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Kaufman DS, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038–42.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Toriz NH, Feldman R, Tammela TLJ, Saad F. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–55.
   PubMed Web of Science ®Google Scholar
• Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifen to prevent gonadotropin releasing-hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841–6.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8.
   PubMed Web of Science ®Google Scholar
• Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the medical research council trial. Br J Urol 1997;79:235–46.
   PubMedGoogle Scholar
• Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007;100:749–54.
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Coates PM, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410–17.
   PubMed Web of Science ®Google Scholar
• Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, et al. Bone mineral density changes in patients with prostate cancer during first 2 years of androgen suppression. J Urol 2006;175:1679–83.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer. Uroweb. 2013. Available at http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf. Accessed March 6, 2013.
   Google Scholar
• Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 2006;24:1868–76.
   PubMed Web of Science ®Google Scholar
• Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, et al. Using PSA to guide timing of androgen deprivation in patients with T0–4 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941–9.
   PubMed Web of Science ®Google Scholar
• Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Eur Urol 2013;63:111–20.
   PubMed Web of Science ®Google Scholar
• Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004;171:2272–6.
   PubMed Web of Science ®Google Scholar
• Shanihian VB, Kuo Y-F, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010;363:1822–32.
   Google Scholar
• Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009;55:62–75.
   PubMed Web of Science ®Google Scholar